menu
    • menu
    PHARMACOMPASS
    PHARMACOMPASS

    Grow Your Pharma Business Digitally
    X
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Innovent Announces 2024 Annual Results and Business Updates

    PR NEWSWIRE

    Eli Lilly`s goal is to reach everyone who needs obesity care

    ECONOMICTIMES

    Lilly reveals 2025 AACR Annual Meeting presentations

    PR NEWSWIRE

    Organovo Sells FXR Program to Eli Lilly and Company

    GLOBENEWSWIRE

    Eli launches Mounjaro in India after drug regulator approval

    REUTERS

    Lilly, J&J boosted spending on security after UnitedHealth shooting

    REUTERS

    Lilly, J&J Boosted Executive Security Spend After UNH Shooting

    REUTERS

    Eli Lilly plans to launch weight-loss drug in emerging markets this year

    REUTERS

    Lilly`s Baricitinib Shows High Hair Regrowth In AA Adolescents

    PR NEWSWIRE

    Lilly’s Ebglyss Shows 3-Year Clear Skin In Atopic Dermatitis

    PR NEWSWIRE

    NICE again rejects Alzheimer`s drugs from Lilly and Biogen/Eisai

    FIERCE PHARMA

    US judge bars copies of Lilly weight-loss drug

    REUTERS

    LifeMD Integrates LillyDirect For Zepbound GLP-1/GIP Access

    GLOBENEWSWIRE

    Teladoc Adds GLP-1 Self-Pay Option To Weight Care Program

    GLOBENEWSWIRE

    Judge Denies Injunction, Restricting Copies Of Lilly’s Weight-Loss Drug

    REUTERS

    Aspen says new Latam and Eli Lilly portfolio boosting earnings

    REUTERS

    Eli Lilly feels Magnet`s pull with hefty molecular glue deal

    FIERCE BIOTECH

    CHMP Recommends Lilly’s Jaypirca For Relapsed/Refractory CLL

    PR NEWSWIRE

    Lilly To Participate In Leerink Global Healthcare Conference

    PR NEWSWIRE

    Lilly offers weight-loss drugs in vials at a discount

    PRESS RELEASE

    Lilly plans to invest $27B in new plants as Trump threatens tariffs

    PRESS RELEASE

    Lilly pays $10M upfront for Organovo’s FXR agonist program

    ENDPTS

    Eli Lilly makes Zepbound vials cheaper for self-paying patients

    FIERCE PHARMA

    Organovo`s FXR Program, including FXR314, Acquired by Eli Lilly

    GLOBENEWSWIRE

    Nimbus Therapeutics Achieves Milestone in Collaboration with Lilly

    BUSINESSWIRE

    Eli Lilly bets big on weight-loss pill with $550 M inventory

    REUTERS

    Eli Lilly bets big on weight-loss pill with $550 million inventory stockpile

    REUTERS

    Lilly to join TD Cowen`s 45th Health Care Conference

    PR NEWSWIRE

    Kenai Therapeutics Opens Research Facility At Lilly Gateway Labs

    BUSINESSWIRE

    Lilly inks OliX deals to expand in MASH

    BUSINESSWIRE

    Lilly inks AdvanCell deals to expand in radiopharma

    BUSINESSWIRE

    Lilly’s Omvoh® Achieves Sustained Remission in Crohn’s Disease

    PR NEWSWIRE

    Lilly reports Q4 2024 financial results & provides 2025 guidance

    PR NEWSWIRE

    Eli Lilly appoints Winselow as President & General Manager for India

    EXPRESS PHARMA

    Lilly needs a plan to spur weight-loss drug sales, investors say

    REUTERS

    Lilly Cuts Mid-stage Relaxin Study in Chronic Kidney Disease

    BIOSPACE

    Novo to cap insulin prices in settlement; joins Lilly, Sanofi

    REUTERS

    Lilly Sets Date For Q4 2024 Results & 2025 Guidance Announcement

    PR NEWSWIRE

    Study of Novo, Lilly weight loss drugs show decrease in Alzheimer`s

    FIERCE PHARMA

    US FDA approves expanded use of Lilly`s bowel disease drug

    PRESS RELEASE

    Eli lilly`s Biologic Omvoh Receives Suppl Approval in US

    FDA

    Eli Lilly misses 2024 revenue expectations, stock dips 7%

    ENDPTS

    Lilly provides update on 2024 revenue guidance

    PR NEWSWIRE

    Eli Lilly to buy Scorpion cancer therapy for up to $2.5 billion

    REUTERS

    In a unique collab, Lilly and a16z forge new $500M venture fund

    FIERCE BIOTECH

    Mediar, Lilly License Antibody for Idiopathic Pulmonary Fibrosis

    PR NEWSWIRE

    Lilly crafts deal with UK biotech for new ALS antibodies

    PRNEWS WIRE

    Alchemab, Lilly Collaborate to Develop Therapies for ALS

    PR NEWSWIRE

    Lilly to establish new global capability centre in Hyderabad

    EXPRESSPHARMA

    Wegovy and Zepbound tipped to fuel $20B heart failure boom

    FIERCE PHARMA

    Novo, Lilly launches top Clarivate`s `Drugs to Watch` list

    FIERCE PHARMA

    Lilly to participate in J.P. Morgan Healthcare Conference

    PR NEWSWIRE

    Roche projected to claim pharma`s 2025 sales crown

    FIERCE PHARMA

    Lilly seeks to intervene in compounded tirzepatide lawsuit

    FIERCE PHARMA

    Lilly Joins Lawsuit Over Compounded Weight-Loss Drugs

    REUTERS

    Novo, Lilly poised to overcome GLP-1 supply constraints in 2025

    FIERCE PHARMA

    Teva looks to peel back the onion on mental health

    FIERCE PHARMA

    Lilly’s Zepbound set to ‘dominate’ obesity market

    FIERCE PHARMA

    Lupin acquires Huminsulin from Lilly, enhance diabetes portfolio

    INDPHARMAPOST

    Lilly drug Mounjaro offered in Britain`s NHS after watchdog nod

    REUTERS

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.